Search Medical Condition
Please enter condition
Please choose location from dropdown

Fallopian Tube Cancer Clinical Trials

A listing of Fallopian Tube Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (123) clinical trials

This is an open label study, active-controlled, multi-center study. The total duration of the study will be approximately 64 months. The screening phase may last up to 30 days. If the results of the procedures done during the screening period allow study participation, there will be randomization into 1 of ...

Phase

You are being asked to take part in this study because you have high grade serous ovarian primary peritoneal or fallopian tube cancer. Standard chemotherapy for your type of cancer usually consists of two drugs called carboplatin and paclitaxel. This treatment has been found to be effective, but many subjects ...

Phase

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00719303?term=GOG+0225&rank=1

Phase N/A

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01366183?term=GOG+0273&rank=1

Phase N/A

Winthrop University Hospital Gynecologic Oncology Department is seeking volunteers who have been diagnosed with Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer and are willing to participate in a clinical research study to see if an investigational vaccine is safe and effective. Eligible participants will receive the ...

Phase N/A

People with ovarian cancer are asked to participate in a research study being conducted by Montefiore Medical Center.

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian Fallopian Tube or Primary Peritoneal Cancer Undergoing Surgery

PRIMARY OBJECTIVES: I. Determine whether the addition of an IGFBP-2 vaccine to neoadjuvant chemotherapy increases the rate of complete pathologic response (CR). SECONDARY OBJECTIVES: I. Determine whether the addition of an IGFBP-2 vaccine to neoadjuvant chemotherapy increases progression free survival at 12 months. II. Determine whether the addition of an ...

Phase

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian Fallopian or Peritoneal Cancer

PRIMARY OBJECTIVES: I. Compare clinical efficacy of Arm A (MV-NIS therapy) and Arm B (standard cytotoxic chemotherapy), as measured by overall survival (OS). SECONDARY OBJECTIVES: I. Compare progression-free survival (PFS), overall survival at 12 months (OS12), progression-free survival at six months (PFS6), and objective response rate (ORR) between MV-NIS therapy ...

Phase

DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Poly ICLC and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian Fallopian Tube or Primary Peritoneal Cancer in Remission

PRIMARY OBJECTIVES: I. To determine the safety of fixed doses of DEC205mAb-NY-ESO-1 fusion protein (DEC-205/NY-ESO-1 fusion protein CDX-1401) with adjuvant poly-ICLC given as a vaccine in combination with INCB024360 (IDO1 inhibitor INCB024360). (Phase I) II. To evaluate toxicity as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse ...

Phase